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received treatment with amlodipine while 14 received
treatment with other antihypertensives, primarily beta
blockers (n¼11). A signiﬁcant difference was not found in
the primary or secondary endpoints, which assessed safety
and efﬁcacy between the treatment groups. Signiﬁcant
differences were found between those with and those
without cyclosporine-induced hypertension. Patients with
cyclosporine-induced hypertension had a longer mean
length of stay, 35.4 days (18-109) as compared to 24.1 days
(7-74). Zero of the 9 patients who received amlodipine
prior to and during the BMT admission went on to expe-
rience cyclosporine-induced hypertension. Available
results, although not robust, suggest that safety and efﬁ-
cacy are similar in allogeneic BMT patients whether they
receive amlodipine or another antihypertensive to treat
cyclosporine-induced hypertension. However, the data
provided did identify that those patients receiving amlo-
dipine prior to and during their bone marrow transplant
were less likely to experience cyclosporine-induced
hypertension.545
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Background: Peri-transplant iron overload (IOL) has been
associated with increased non-relapse morbidity and
mortality in patients receiving hematopoietic stem cell
transplant (HSCT). Iron chelation therapy (ICT) with
deferoxamine or deferasirox, and phlebotomy remain the
major therapeutic options for reducing IOL in HSCT recip-
ients, though the role of ICT in these patients, particularly
in the post-transplant period, has not been clearly deﬁned.
The aim of this study was to evaluate the impact of
post-transplant ICT on outcomes up to day +100 in allo-
geneic HSCT, and to assess the tolerability of post-trans-
plant ICT.
Methods: A retrospective medical record review of 29
patients who underwent allogeneic HSCT from March 2009
to October 2011 at a 779-licensed bed, urban academic
medical center was conducted. Inclusion criteria were age 
18 years and serum ferritin level  1000 ng/mL within 3
months prior to transplant. Exclusion criteria were mis-
matched or cord blood transplant, and ICT initiated in the
pre-transplant period or after day +50. Patients were divided
into 2 groups: those who received  1 dose of deferoxamine
or deferasirox post-transplant up to day +50 (ICT group), and
those who had never received ICT (non-ICT group). The
primary endpoint was clinically signiﬁcant liver dysfunction
up to day +100.
Results: Of the 29 patients evaluated, 22 were in the non-
ICT group and 7 in the ICT group (6 received deferoxamine
1000 mg IV daily, 1 received deferasirox 2000 mg orally
daily; median duration of ICT, 24 days). There were no
statistically signiﬁcant differences between the groups in
demographic or transplant characteristics, though there
was a longer median time from diagnosis to transplant
(417 vs. 238 days, P ¼ .37) and a higher median pre-
transplant ferritin level (2910 vs. 1673 ng/mL, P ¼ .38) in
the ICT group compared to the non-ICT group. Four
patients experienced clinically signiﬁcant liver dysfunc-
tion, with 3 patients (13.6%) in the non-ICT group and 1patient (14.3%) in the ICT group (P ¼ .99). There were no
signiﬁcant differences in other post-transplant outcomes
evaluated, including change in ferritin level, bloodstream
infection, and death. Of the 7 ICT patients, 71.4% experi-
enced acute kidney injury that required interruption or
discontinuation of ICT.
Conclusions: ICT in the immediate post-transplant period
did not improve post-transplant outcomes and was not well
tolerated. Alternative strategies for the administration of
pre- or peri-transplant ICT in HSCT recipients are recom-
mended.546
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Background: Linezolid (LZ) is an oxazolidinone antimicro-
bial often used to treat resistant gram-positive bacteria and
has been associated with mild, reversible, time-dependent
myelosuppression, including thrombocytopenia (common),
anemia (common), leukopenia, and pancytopenia. Gener-
ally, these effects occur with treatment durations of  14
days. Patients with underlying hematologic abnormalities
may be more at risk for the development of LZ-induced
myelosuppression, but this is controversial. We hypothe-
sized that LZ use before engraftment may delay hemato-
poietic recovery following stem cell transplant (SCT), and
performed a matched controlled analysis to investigate this
hypothesis.
Methods: With institutional review board approval, we
retrospectively evaluated 24 patients who received LZ and
compared them to 60 controls who did not receive LZ from 1/
1/1997 to 1/1/2010. Our SCT database was utilized to ﬁnd
matched controls and matching was based on: diagnosis;
transplant type; cell source; transplant conditioning
regimen; and age +/- 10 years. Patients in the LZ group were
included if LZ was administered at any time from day
0 through engraftment of white cells but for a minimum of
72 consecutive hours. Patients 1 year of age or older were
included. The datawere analyzed for the effects of LZ on time
to neutrophil (ANC > 500 for 3 days) and platelet engraft-
ment (platelet count > 20,000 for 7 days without trans-
fusion), and the cumulative incidence of engraftment of both
neutrophil and platelets within the ﬁrst 100 days post-
transplant.
Results: The LZ and control groups were similar with
respect to age (median 44 vs. 41 years), gender (50% vs. 58%
male and 50% vs. 42% female), diagnosis (29% vs. 25% had
AML/MDS), cell source (67% vs. 63% apheresis product),
transplant type (67% vs. 63% allogeneic), ablative vs. non-
ablative conditioning (79% vs. 83% myeloablative), and cell
dose (median CD34 dose 4.52 x 106/kg vs. 4.34 x 106/kg).
Median time to neutrophil engraftment was the same for LZ
and control groups (12 days). The median time to neutro-
phil plus platelet engraftment for LZ group and control
group was 50 days (11 patients censored) vs. 15.5 days (10
patients censored). Neutrophil engraftment failure occurred
Table
Association betweenMPA total serum trough levels and toxicity and efﬁcacy
outcomes
1A) Toxicity outcome: Time-dependent Cox regression
Outcome N HR (95% CI) P-value
Time to neutrophils
 0.5 k/mcL
61 1.45 (0.65 - 3.25) 0.36
Time to platelets
 20 k/mcL
61 1.88 (0.82 - 4.30) 0.14
Time to TPN cessation 61 0.56 (0.20 - 1.58) 0.28
Time to CMV viremia 31 1.71 (0.38 - 7.59) 0.48
IB) Efﬁcacy outcome: Cumulative incidence of aGVHD by day 100
Outcome N Cumulative incidence
(95% CI)
P-value
aGVHD II-IV
Trough < 0.5 mcg/mL 15 0.67 (0.41 - 0.92) 0.29
Trough  0.5 mcg/mL 57 0.57(0.44 - 0.71)
aGVHD III-IV
Trough < 0.5 mcg/mL 15 0.27 (0.03 - 0.50) 0.12
Trough < 0.5 mcg/mL 57 0.11 (0.03 - 0.19)
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LZ patients vs. 13% of controls failed to achieve platelet
engraftment. The cumulative incidence of engraftment of
neutrophils plus platelets (using death without engraftment
as the competing risk) was lower in the LZ group (54%) vs.
the control group (83%) (P ¼ .005). Day 100 survival rates
were 58% for the LZ group vs. 92% for controls. Survival
probability is shown in Figure 1.
Conclusions: LZ does not signiﬁcantly affect time to
neutrophil engraftment, but does appear to prolong time to
platelet engraftment when compared to patients who did
not receive LZ. LZ should be used cautiously early after stem
cell transplantation.
Figure 1. Overall Survival
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Background: Mycophenolate mofetil (MMF) is frequently
combined with cyclosporine-A as immunosuppression in
unrelated donor CBT. Recent evidence suggests that thera-
peutic drug monitoring of mycophenolic acid (MPA), the
active metabolite of MMF, is advisable based on intra- and
inter-patient variability of MMF pharmacokinetics (PK).
Moreover, an increased incidence of acute graft-versus-host
disease (aGVHD) has been associated with low unbound
MPA AUCs in adult allograft recipients. This is highly rele-
vant in CBT as aGVHD is a leading cause of transplant-
related mortality. However, as AUCs are cumbersome,
a limited PK parameter such as MPA troughs would be ideal.
Also, the toxicity associated with MPA trough levels is not
established.
Methods: We evaluated the association between serial MPA
total serum trough levels in weeks 1-6 and transplant
outcomes in pediatric and adult double-unit CB recipients
transplanted 8/2009 to 6/2012 for hematologic malignancies
with 4-6/6 HLA-A,B antigen, DRB1 allele matched CB grafts.
To evaluate the association between trough levels andoutcomes, the trough levels were dichotomized into < 2
mcg/mL and  2 mcg/mL for toxicity (delayed engraftment,
gastrointestinal toxicity, viral infection), and < 0.5 mcg/mL
and  0.5 mcg/mL for efﬁcacy (aGVHD prevention) at each
time point.
Results: Seventy-four patients had MPA total serum trough
levels drawn weekly for 6 weeks. Sixty-one (82%) received
myeloablative (MA) conditioning and 31 (42%) were CMV
seropositive. Median trough levels by week were 0.9, 0.9,
0.6, 0.7, 0.9, and 1.3 mcg/mL. The change in trough levels
over time did not reach signiﬁcance (P ¼ .07). Recipients
of MA conditioning had lower MPA troughs than those
who received non-myeloablative conditioning (P ¼ .03). By
time-dependent Cox regression analysis, there was no
association between trough levels and toxicity as
measured by time to neutrophil and platelet recovery or
duration of total parenteral nutrition (TPN) in myeloa-
blative CBT recipients, or time to viremia in CMV sero-
positive patients (Table 1A). In a competing risk 2-week
landmark analysis, while differences between groups did
not reach signiﬁcance, it was notable that the incidence of
severe (grade III-IV) aGVHD was more than doubled in
those with a mean week 1 and 2 trough level < 0.5 mcg/
mL (Table 1B).
Conclusions: Analysis of this limited patient population
suggests that while MPA total serum trough levels appear to
have little effect on toxicity outcomes, the early post-trans-
plant (week 1-2) mean levels could be associated with the
risk of severe (grade III-IV) aGVHD. Further investigation in
a larger patient series is warranted.548
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